138 results on '"Azab, Abed N."'
Search Results
2. The Role of FKBPs in Complex Disorders: Neuropsychiatric Diseases, Cancer, and Type 2 Diabetes Mellitus.
- Author
-
Agam, Galila, Atawna, Bayan, Damri, Odeya, and Azab, Abed N.
- Subjects
TYPE 2 diabetes ,NEUROBEHAVIORAL disorders ,TAU proteins ,ALZHEIMER'S disease ,HUNTINGTON disease ,SINGLE nucleotide polymorphisms ,HUNTINGTIN protein ,PEROXISOME proliferator-activated receptors - Abstract
Stress is a common denominator of complex disorders and the FK-506 binding protein (FKBP)51 plays a central role in stress. Hence, it is not surprising that multiple studies imply the involvement of the FKBP51 protein and/or its coding gene, FKBP5, in complex disorders. This review summarizes such reports concentrating on three disorder clusters—neuropsychiatric, cancer, and type 2 diabetes mellitus (T2DM). We also attempt to point to potential mechanisms suggested to mediate the effect of FKBP5/FKBP51 on these disorders. Neuropsychiatric diseases considered in this paper include (i) Huntington's disease for which increased autophagic cellular clearance mechanisms related to decreased FKBP51 protein levels or activity is discussed, Alzheimer's disease for which increased FKBP51 activity has been shown to induce Tau phosphorylation and aggregation, and Parkinson's disease in the context of which FKBP12 is mentioned; and (ii) mental disorders, for which significant association with the single nucleotide polymorphism (SNP) rs1360780 of FKBP5 intron 7 along with decreased DNA methylation were revealed. Since cancer is a large group of diseases that can start in almost any organ or tissue of the body, FKBP51's role depends on the tissue type and differences among pathways expressed in those tumors. The FKBP51–heat-shock protein-(Hsp)90–p23 super-chaperone complex might function as an oncogene or as a tumor suppressor by downregulating the serine/threonine protein kinase (AKt) pathway. In T2DM, two potential pathways for the involvement of FKBP51 are highlighted as affecting the pathogenesis of the disease—the peroxisome proliferator-activated receptor-γ (PPARγ) and AKt. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction.
- Author
-
Arbel, Ronen, Azab, Abed N., Oberoi, Mansi, Aboalhasan, Enis, Star, Artyom, Elhaj, Khaled, Khalil, Fouad, and Alnsasra, Hilmi
- Subjects
ENTRESTO ,DAPAGLIFLOZIN ,VENTRICULAR ejection fraction ,HEART failure ,MEDICAL care costs - Abstract
Background and aim: Heart failure with preserved ejection fraction (HFpEF) is associated with an increased risk of heart failure (HF) hospitalizations and cardiovascular death (CVD). Both dapagliflozin and sacubitril-valsartan have recently shown convincing reductions in the combined risk of CVD and HF hospitalizations in patients with HF and mildly reduced ejection fraction (HFmrEF) or HFpEF. We aimed to investigate the cost-per-outcome implications of dapagliflozin vs sacubitril-valsartan in the treatment of HFmrEF or HFpEF patients. Methods: We compared the annualized cost needed to treat (CNT) to prevent the composite outcome of total HF hospitalizations and CVD with dapagliflozin or sacubitril-valsartan. The CNT was estimated by multiplying the annualized number needed to treat (aNNT) by the annual cost of therapy. The aNNT was calculated based on data collected from the DELIVER trial for dapagliflozin and a pooled analysis of the PARAGLIDE-HF and PARAGON-HF trials for sacubitril-valsartan. Costs were based on 2022 US prices. Scenario analyses were performed to attenuate the differences in the studies' populations. s Results: The aNNT with dapagliflozin in DELIVER was 30 (95% confidence interval [CI]: 21-62) versus 44 (95% CI: 25-311) with sacubitril-valsartan in a pooled analysis of PARAGLIDE-HF and PARAGON-HF, with an annual cost of $4,951 and $5,576, respectively. The corresponding CNTs were $148,547.13 (95% CI: $103,982.99-$306,997.39) for dapagliflozin and $245,346.77 (95% CI: $139,401.58-1,734,155.60) for sacubitril-valsartan for preventing the composite outcome of CVD and HF hospitalizations. The CNT for preventing all-cause mortality was lower for dapagliflozin than sacubitril-valsartan $1,128,958.15 [CI: $401,077.24-8] vs $2,185,816.71 [CI: $607,790.87-8]. Conclusion: Dapagliflozin provides a better monetary value than sacubitril-valsartan in preventing the composite outcome of total HF hospitalizations and CVD among patients with HFmrEF or HFpEF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures.
- Author
-
Guy, Amit, Azab, Abed N., Liberty, Idit F., Afawi, Zaid, Alhoashla, Ali, and Abu Tailakh, Muhammad
- Subjects
- *
LIRAGLUTIDE , *ANTIOBESITY agents , *OBESITY , *BODY mass index , *PATIENT compliance , *ODDS ratio , *MORBID obesity , *CHILDHOOD obesity - Abstract
Aim: To identify the sociodemographic, clinical and laboratory determinants relating to patient adherence to liraglutide treatment among individuals with overweight or obesity. Methods: We retrospectively analysed patients with overweight or obesity who were treated with liraglutide between 2019 and 2022. Over a 6‐month follow‐up period, measurements of body mass index, sociodemographic characteristics, clinical and laboratory data, and prescription records for liraglutide were collected. Treatment adherence was assessed using the proportion of days covered (PDC) measure, with a PDC ≥80% indicating high adherence. Results: The study population included 1890 participants (78.1% female, mean age 46 ± 12 years). At the end of the follow‐up period, 84.9% of the participants exhibited low adherence to liraglutide treatment. Adherence to treatment improved with age (p = 0.04, odds ratio [OR] 1.013, confidence interval [CI] 1.001–1.025). Significant weight loss during treatment increased the likelihood of high adherence (p < 0.001, OR 1.251, CI 1.167–1.341). Individuals with a higher socioeconomic status displayed greater adherence (p = 0.023, OR 1.906, CI 1.091–3.328). Greater adherence was also seen in non‐smokers (p = 0.047, OR 0.725, CI 0.528–0.996). Conclusions: Only 15.1% of study participants exhibited high adherence to treatment (PDC ≥80%) after 6 months of follow‐up. Further research is needed to explore approaches to enhance adherence to liraglutide, including strategies to educate and support patients in their efforts to achieve and maintain weight loss with the use of this drug. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Vaccinating without complete willingness against COVID‐19: Personal and social aspects of Israeli nursing students and faculty members.
- Author
-
Biton, Linoy, Shvartsur, Rachel, Grinberg, Keren, Kagan, Ilya, Linetsky, Irena, Halperin, Ofra, Azab, Abed N., and Cohen, Odeya
- Subjects
IMMUNIZATION ,CROSS-sectional method ,POST-traumatic stress disorder ,RESEARCH funding ,T-test (Statistics) ,VACCINATION ,PILOT projects ,LOGISTIC regression analysis ,ISRAELIS ,DESCRIPTIVE statistics ,COVID-19 vaccines ,MULTIVARIATE analysis ,ATTITUDE (Psychology) ,ODDS ratio ,COLLEGE teacher attitudes ,PERSONALITY ,DRUG efficacy ,STATISTICS ,STUDENT attitudes ,DATA analysis software ,CONFIDENCE intervals ,NURSING students ,COVID-19 ,COVID-19 pandemic - Abstract
Soon after the coronavirus disease 2019 (COVID‐19) pandemic outbreak, it became clear that vaccination will be the most useful tool to combat the disease. Despite the apparent safety and efficacy of the developed anti‐COVID‐19 vaccines, relatively high percentages of the population worldwide refused to get vaccinated, including many health workers and health students. The present cross‐sectional study examined the motives, attitudes, and personal characteristics of those who did not get vaccinated against COVID‐19 or vaccinated without complete willingness among nursing students and nursing faculty members in Israel (n = 472). Results show that the vast majority of the study participants (97%) received at least one dose of the anti‐COVID‐19 vaccine. Nearly 37% of the participants indicated that they received the vaccine without complete willingness. As compared to faculty members, nursing students reported lower trust in the efficacy of the vaccine, perceived the COVID‐19 pandemic as a health threat to a lesser extent, exhibited lower institutional and personal trust, and had higher levels of posttraumatic stress disorder symptoms. Non‐Jewish participants were at risk of vaccinating without complete willingness. These findings underscore the need for developing evidence‐based strategies to promote the safety and efficacy of the anti‐COVID‐19 vaccines in nursing schools. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
- Author
-
Bloch, Yehudit, Belmaker, R. H., Shvartzman, Pesach, Romem, Pnina, Bolotin, Arkady, Bersudsky, Yuly, and Azab, Abed N.
- Published
- 2021
- Full Text
- View/download PDF
7. Chronic Treatment with Nigella sativa Oil Exerts Antimanic Properties and Reduces Brain Inflammation in Rats.
- Author
-
Uzzan, Sarit, Rostevanov, Ira-Sivan, Rubin, Elina, Benguigui, Olivia, Marazka, Said, Kaplanski, Jacob, Agbaria, Riad, and Azab, Abed N.
- Subjects
BLACK cumin ,ENCEPHALITIS ,INFLAMMATORY mediators ,RATS ,MENTAL illness ,DINOPROSTONE - Abstract
Nigella sativa (NS) is a native herb consumed habitually in several countries worldwide, possessing manifold therapeutic properties. Among them, anti-inflammatory features have been reported, presumably relating to mechanisms involved in the nuclear factor kappa-B pathway, among others. Given the observed association between neuroimmune factors and mental illness, the primary aim of the present study was to examine the effects of chronic NS use on manic-like behavior in rats, as well as analyze levels of brain inflammatory mediators following NS intake. Using male and female rats, baseline tests were performed; thereafter, rats were fed either regular food (control) or NS-containing food (treatment) for four weeks. Following intervention, behavioral tests were induced (an open field test, sucrose consumption test, three-chamber sociality test, and amphetamine-induced hyperactivity test). Subsequently, brain samples were extracted, and inflammatory mediators were evaluated, including interleukin-6, leukotriene B4, prostaglandin E2, tumor necrosis factor-α, and nuclear phosphorylated-p65. Our findings show NS to result in a marked antimanic-like effect, in tandem with a positive modulation of select inflammatory mediators among male and female rats. The findings reinforce the proposed therapeutic advantages relating to NS ingestion. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Developing and validating a prognostic index predicting re-hospitalization of patients with Hyperemesis Gravidarum
- Author
-
Morris, Zohar H., Azab, Abed N., Harlev, Shlomit, and Plakht, Ygal
- Published
- 2018
- Full Text
- View/download PDF
9. Short and long-term prognosis following acute myocardial infarction according to the country of origin. Soroka acute myocardial infarction II (SAMI II) project
- Author
-
Shvartsur, Rachel, Shiyovich, Arthur, Gilutz, Harel, Azab, Abed N., and Plakht, Ygal
- Published
- 2018
- Full Text
- View/download PDF
10. The Association Between Psychotropic Drug Use and Fertility Problems Among Male Subjects
- Author
-
SOLOMON, RONNIE, SHVARTSUR, RACHEL, and AZAB, ABED N.
- Published
- 2019
- Full Text
- View/download PDF
11. Dapagliflozin versus empagliflozin in patients with chronic kidney disease.
- Author
-
Alnsasra, Hilmi, Tsaban, Gal, Solomon, Adam, Khalil, Fouad, Aboalhasan, Enis, Azab, Abed N., Azuri, Joseph, Hammerman, Ariel, and Arbel, Ronen
- Subjects
EMPAGLIFLOZIN ,CHRONIC kidney failure ,DAPAGLIFLOZIN ,CHRONICALLY ill ,COST allocation ,VALUE (Economics) - Abstract
Background and Aim: Dapagliflozin and empagliflozin have demonstrated favorable clinical outcomes among patients with chronic kidney disease (CKD). However, their comparative monetary value for improving outcomes in CKD patients is unestablished. We examined the cost-per-outcome implications of utilizing dapagliflozin as compared to empagliflozin for prevention of renal and cardiovascular events in CKD patients. Methods: For calculation of preventable events we divided the allocated budget by the cost needed to treat (CNT) for preventing a single renal or cardiovascular event. CNT was derived by multiplying the annualized number needed to treat (aNNT) by the annual therapy cost. The aNNTs were determined based on data from the DAPA-CKD and EMPEROR-KIDNEY trials. The budget limit was defined based on the threshold recommended by the United States' Institute for Clinical and Economic Review. Results: The aNNT was 42 both dapagliflozin (95% confidence interval [CI]: 34-59) and empagliflozin (CI: 33-66). The CNT estimates for the prevention of one primary event for dapagliflozin and empagliflozin were comparable at $201,911 (CI: $163,452-$283,636) and $209,664 (CI: $164,736-$329,472), respectively. However, diabetic patients had a higher CNT with dapagliflozin ($201,911 [CI: $153,837-$346,133]) than empagliflozin ($134,784 [CI: $109,824-$214,656]), whereas non-diabetic patients had lower CNT for dapagliflozin ($197,103 [CI: $149,029-$346,133]) than empagliflozin ($394,368 [CI: $219,648-$7,093,632]). The CNT for preventing CKD progression was higher for dapagliflozin ($427,858 [CI: $307,673-$855,717]) than empagliflozin ($224,640 [CI: $169,728-$344,448]). For preventing cardiovascular death (CVD), the CNT was lower for dapagliflozin ($1,634,515 [CI: $740,339-∞]) than empagliflozin ($2,990,208 [CI: $1,193,088-∞]). Conclusion: Among patients with CKD, empagliflozin provides a better monetary value for preventing the composite renal and cardiovascular events in diabetic patients while dapagliflozin has a better value for non-diabetic patients. Dapagliflozin provides a better monetary value for the prevention of CVD, whereas empagliflozin has a better value for the prevention of CKD progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Depression among Patients with an Implanted Left Ventricular Assist Device: Uncovering Pathophysiological Mechanisms and Implications for Patient Care.
- Author
-
Alnsasra, Hilmi, Khalil, Fouad, Kanneganti Perue, Radha, and Azab, Abed N.
- Subjects
HEART assist devices ,MENTAL depression ,TRANSCRANIAL magnetic stimulation ,PATIENT care ,DEEP brain stimulation ,ATTEMPTED suicide ,DEPRESSED persons ,HEART failure patients - Abstract
Depression is a common and devastating mental illness associated with increased morbidity and mortality, partially due to elevated rates of suicidal attempts and death. Select patients with end-stage heart failure on a waiting-list for a donor heart undergo left ventricular assist device (LVAD) implantation. The LVAD provides a circulatory flow of oxygenated blood to the body, mimicking heart functionality by operating on a mechanical technique. LVAD improves functional capacity and survivability among patients with end-stage heart failure. However, accumulating data suggests that LVAD recipients suffer from an increased incidence of depression and suicide attempts. There is scarce knowledge regarding the pathological mechanism and appropriate treatment approach for depressed LVAD patients. This article summarizes the current evidence on the association between LVAD implantation and occurrence of depression, suggesting possible pathological mechanisms underlying the device-associated depression and reviewing the current treatment strategies. The summarized data underscores the need for a rigorous pre-(LVAD)-implantation psychiatric evaluation, continued post-implantation mental health assessment, and administration of antidepressant treatment as necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes.
- Author
-
Masarwe, Sabaa, Shvartsur, Rachel, Hadar, Eran, Betesh-Abay, Batya, Peleg, Noam, and Azab, Abed N.
- Subjects
CLEFT lip -- Risk factors ,MORNING sickness ,MATERNAL exposure ,PREMATURE infants ,HUMAN abnormalities ,CLEFT palate ,CONGENITAL heart disease ,SPINA bifida ,RETROSPECTIVE studies ,GESTATIONAL age ,ACQUISITION of data ,PREGNANCY outcomes ,RISK assessment ,COMPARATIVE studies ,PERINATAL death ,SEX distribution ,T-test (Statistics) ,ONDANSETRON ,PREGNANCY complications ,BIRTH weight ,MEDICAL records ,CHI-squared test ,DESCRIPTIVE statistics ,DATA analysis software ,SMOKING ,SMALL for gestational age ,DISEASE risk factors ,PREGNANCY - Abstract
Ondansetron is a widely administered medication for nausea and vomiting of pregnancy. Further examination of its teratogenic capacity is necessary. This study examines the association between ondansetron treatment during pregnancy and birth defects and adverse obstetric outcomes. Patient data were extracted from Clalit Health Services, Israel. A propensity-score analysis was performed matching those exposed to ondansetron with those who were not. Findings identified 774 women exposed to ondansetron, matched 1:1 with unexposed control patients. No significant differences were found between the groups for: cleft palate, cardiovascular congenital abnormalities, spina bifida occulta, preterm delivery, or small for gestational age. Ondansetron may be a useful and safe alternative as treatment for women who suffer from hyperemesis gravidarum and do not respond to other antiemetic drugs. Notwithstanding, additional prospectively designed research is needed to establish the safety of ondansetron treatment during pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Lithium nephrotoxicity
- Author
-
Azab, Abed N., Shnaider, Alla, Osher, Yamima, Wang, Dana, Bersudsky, Yuly, and Belmaker, R. H.
- Published
- 2015
- Full Text
- View/download PDF
15. The Integrity of the Blood–Brain Barrier as a Critical Factor for Regulating Glutamate Levels in Traumatic Brain Injury.
- Author
-
Boyko, Matthew, Gruenbaum, Benjamin F., Frank, Dmitry, Natanel, Dmitry, Negev, Shahar, Azab, Abed N., Barsky, Guy, Knyazer, Boris, Kofman, Ora, and Zlotnik, Alexander
- Subjects
BLOOD-brain barrier ,BRAIN injuries ,GLUTAMIC acid ,CEREBROSPINAL fluid - Abstract
A healthy blood–brain barrier (BBB) shields the brain from high concentrations of blood glutamate, which can cause neurotoxicity and neurodegeneration. It is believed that traumatic brain injury (TBI) causes long-term BBB disruption, subsequently increasing brain glutamate in the blood, in addition to increased glutamate resulting from the neuronal injury. Here, we investigate the relationship between blood and brain glutamate levels in the context of BBB permeability. Rats exposed to BBB disruption through an osmotic model or TBI and treated with intravenous glutamate or saline were compared to control rats with an intact BBB treated with intravenous glutamate or saline. After BBB disruption and glutamate administration, the concentrations of glutamate in the cerebrospinal fluid and blood and brain tissue were analyzed. The results showed a strong correlation between the brain and blood glutamate concentrations in the groups with BBB disruption. We conclude that a healthy BBB protects the brain from high levels of blood glutamate, and the permeability of the BBB is a vital component in regulating levels of glutamate in the brain. These findings bring a new approach to treating the consequences of TBI and other diseases where long-term disruption of the BBB is the central mechanism of their development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Staff attitudes and perceptions towards the use of coercive measures in psychiatric patients.
- Author
-
Galbert, Ilya, Azab, Abed N., Kaplan, Zeev, and Nusbaum, Lika
- Subjects
- *
HEALTH facility employees , *HEALTH policy , *NURSES' attitudes , *ATTITUDES of medical personnel , *CROSS-sectional method , *QUANTITATIVE research , *PHYSICIANS' attitudes , *PSYCHOSOCIAL factors , *RESTRAINT of patients , *DESCRIPTIVE statistics , *THEMATIC analysis , *DATA analysis software , *PSYCHIATRIC hospitals , *CONTROL (Psychology) , *CORPORATE culture , *PSYCHOLOGY of physicians - Abstract
The failure of efforts to significantly reduce the use of physical coercive measures (PCMs) in psychiatric hospitals remains a global concern. There is a gap in the understanding of staff's characteristics that may affect their attitudes and perceptions towards PCMs. This study used a cross‐sectional design to examine the attitudes and perceptions of staff working at a mental health centre in Israel regarding the use of PCMs and to explore whether staff attitudes differed depending on their professional and demographic background. This study also sought to explore staff willingness to accept a policy of reducing the use of PCMs. The data were collected from 149 staff members (nurses, physicians, and auxiliary staff) working at mental health centre, using a questionnaire developed for this study. The findings indicate a low degree of support for use of PCMs among participants who were older, female, more qualified psychiatric nurses, with longer duration of employment, and those who have not participated in coercive intervention in the past year. The majority of the sample reported a low willingness to reduce the use of PCMs, and a lack of institutional support after participating in a coercive event. High hospital occupancy and insufficient staffing were perceived as contributing factors to coercive incidents. Therefore, availability of trained and experienced staff, elimination of organizational barriers, along with creating and maintaining a safe clinical environment should be a priority. Alternative non‐coercive interventions should further be taught and used for managing aggressive and violent behaviour in the psychiatric clinical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Ethylbutyrate, a valproate-like compound, exhibits inositol-depleting effects — A potential mood-stabilizing drug
- Author
-
Azab, Abed N., Mehta, Dhara V., Chesebro, John E., and Greenberg, Miriam L.
- Published
- 2009
- Full Text
- View/download PDF
18. Montelukast induces beneficial behavioral outcomes and reduces inflammation in male and female rats.
- Author
-
Rostevanov, Ira S., Betesh-Abay, Batya, Nassar, Ahmad, Rubin, Elina, Uzzan, Sarit, Kaplanski, Jacob, Biton, Linoy, and Azab, Abed N.
- Subjects
TUMOR necrosis factors ,INFLAMMATORY mediators ,MONTELUKAST ,HYPERACTIVITY ,FRONTAL lobe ,RATS - Abstract
Background: Accumulative data links inflammation and immune dysregulation to the pathophysiology of mental disorders; little is known regarding leukotrienes' (LTs) involvement in this process. Circumstantial evidence suggests that treatment with leukotriene modifying agents (LTMAs) such as montelukast (MTK) may induce adverse neuropsychiatric events. Further methodic evaluation is warranted. Objective: This study aims to examine behavioral effects, as well as inflammatory mediator levels of chronic MTK treatment in male and female rats. Methods: Depression-like phenotypes were induced by exposing male and female rats to a chronic unpredictable mild stress (CUMS) protocol for four weeks. Thereafter, rats were treated (intraperitoneally) once daily, for two weeks, with either vehicle (dimethyl sulfoxide 0.2 ml/rat) or 20 mg/kg MTK. Following treatment protocols, behavioral tests were conducted and brain regions were evaluated for inflammatory mediators including tumor necrosis factor (TNF)-a, interleukin (IL)-6 and prostaglandin (PG) E2. Results: Overall, MTK did not invoke negative behavioral phenotypes (except for an aggression-inducing effect in males). Numerous positive behavioral outcomes were observed, including reduction in aggressive behavior in females and reduced manic/hyperactive-like behavior and increased sucrose consumption (suggestive of antidepressant-like effect) in males. Furthermore, in control males, MTK increased IL-6 levels in the hypothalamus and TNF-a in the frontal cortex, while in control females it generated a robust antiinflammatory effect. In females that were subjected to CUMS, MTK caused a prominent reduction in TNF-a and IL-6 in brain regions, whereas in CUMSsubjected males its effects were inconsistent. Conclusion: Contrary to prior postulations, MTK may be associated with select beneficial behavioral outcomes. Additionally, MTK differentially affects male vs. female rats in respect to brain inflammatory mediators, plausibly explaining the dissimilar behavioral phenotypes of sexes under MTK treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Effects of Dexamethasone and Pentoxifylline on Mania-like and Depression-like Behaviors in Rats.
- Author
-
Nassar, Ahmad and Azab, Abed N.
- Subjects
- *
PENTOXIFYLLINE , *RATS , *PEOPLE with mental illness , *CLINICAL trials , *DEXAMETHASONE , *PSYCHIATRIC drugs - Abstract
Several studies support the notion that inflammation plays a role in the pathophysiology and treatment approaches of psychiatric illnesses, particularly mood disorders. Congruently, classic anti-inflammatory drugs were found efficacious in randomized clinical trials of patients with mood disorders. Moreover, accumulating data indicate that psychotropic drugs exhibit some anti-inflammatory effects. This study was undertaken to examine the efficacy of dexamethasone (a potent corticosteroid) and pentoxifylline (a methylxanthine drug with proven anti-tumor necrosis factor-α inhibitory activity) in behavioral models in rats, which were treated intraperitoneally with either dexamethasone or pentoxifylline for two weeks and then subjected to a battery of behavioral tests. Treatment with pentoxifylline, but not dexamethasone, was associated with antidepressant-like and anti-manic-like effects. The beneficial behavioral effects of pentoxifylline were accompanied by a prominent reduction in pro-inflammatory mediator levels in the brain. For the first time, the current work proves the efficacy of pentoxifylline against both mania-like and depressive-like behaviors. These results suggest that pentoxifylline may be a promising therapeutic intervention for patients with mood disorders. Taking into account the excellent tolerability profile of pentoxifylline in humans, it is warranted to conduct randomized clinical trials to investigate its therapeutic efficacy in patients with psychiatric disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. The effects of hemodialysis on blood glutamate levels in chronic renal failure: Implementation for neuroprotection
- Author
-
Rogachev, Boris, Ohayon, Sharon, Saad, Amit, Vorobiovsky, Victoria, Gruenbaum, Benjamin F., Leibowitz, Akiva, Boyko, Matthew, Shapira, Yoram, Shnaider, Alla, Zlotnik, Moshe, Azab, Abed N., and Zlotnik, Alexander
- Published
- 2012
- Full Text
- View/download PDF
21. Low-Dose Aspirin Augments the Anti-Inflammatory Effects of Low-Dose Lithium in Lipopolysaccharide-Treated Rats.
- Author
-
Shvartsur, Rachel, Agam, Galila, Uzzan, Sarit, and Azab, Abed N.
- Subjects
ASPIRIN ,RATS ,LITHIUM carbonate ,BODY temperature ,BIPOLAR disorder ,BRAIN tumors ,MENTAL illness - Abstract
Mounting evidence suggests that immune-system dysfunction and inflammation play a role in the pathophysiology and treatment of mood-disorders in general and of bipolar disorder in particular. The current study examined the effects of chronic low-dose aspirin and low-dose lithium (Li) treatment on plasma and brain interleukin-6 and tumor necrosis factor-α production in lipopolysaccharide (LPS)-treated rats. Rats were fed regular or Li-containing food (0.1%) for six weeks. Low-dose aspirin (1 mg/kg) was administered alone or together with Li. On days 21 and 42 rats were injected with 1 mg/kg LPS or saline. Two h later body temperature was measured and rats were sacrificed. Blood samples, the frontal-cortex, hippocampus, and the hypothalamus were extracted. To assess the therapeutic potential of the combined treatment, rats were administered the same Li + aspirin protocol without LPS. We found that the chronic combined treatment attenuated LPS-induced hypothermia and significantly reduced plasma and brain cytokine level elevation, implicating the potential neuroinflammatory diminution purportedly present among the mentally ill. The combined treatment also significantly decreased immobility time and increased struggling time in the forced swim test, suggestive of an antidepressant-like effect. This preclinical evidence provides a potential approach for treating inflammation-related mental illness. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Mechanisms of action of the mood stabilizer valproate: a focus on GSK-3 inhibition
- Author
-
Azab, Abed N, Ishak, Julia F, Kaplanski, Jacob, Delbar, Vered, and Greenberg, Miriam L
- Published
- 2008
- Full Text
- View/download PDF
23. Inositol depletion: a good or bad outcome of valproate treatment?
- Author
-
Azab, Abed N, Agam, Galila, Kaplanski, Jacob, Delbar, Vered, and Greenberg, Miriam L
- Published
- 2008
- Full Text
- View/download PDF
24. Anticonvulsant efficacy of valproate-like carboxylic acids: a potential target for anti-bipolar therapy
- Author
-
Azab, Abed N and Greenberg, Miriam L
- Published
- 2007
25. Glycogen synthase kinase-3 is required for optimal de novo synthesis of inositol
- Author
-
Azab, Abed N., He, Quan, Ju, Shulin, Li, Guiling, and Greenberg, Miriam L.
- Published
- 2007
26. Lipid connection to bipolar disorder
- Author
-
Azab, Abed N and Greenberg, Miriam L
- Published
- 2006
- Full Text
- View/download PDF
27. Effects of Nimesulide, a Selective Cyclooxygenase-2 Inhibitor, on Cardiovascular Alterations in Endotoxemia
- Author
-
Azab, Abed N., Kobal, Sergio, Rubin, Mazal, and Kaplanski, Jacob
- Published
- 2005
- Full Text
- View/download PDF
28. A reduction of tumor necrosis factor-α in paw exudate of lipopolysaccharide treated rats by nimesulide
- Author
-
Azab, Abed N. and Kaplanski, Jacob
- Published
- 2001
- Full Text
- View/download PDF
29. The Barriers to Neonatal Hepatitis B Vaccination in Israel: A Prospective Study.
- Author
-
Fridman, Elena, Peretz-Aizenman, Liran, and Azab, Abed N.
- Published
- 2020
30. Different roles of cAMP/PKA and PKC signaling in regulating progesterone and PGE2 levels in immortalized rat granulosa cell cultures.
- Author
-
Nemer, Ala, Azab, Abed N., Rimon, Gilad, Lamprecht, Sergio, and Ben-Menahem, David
- Subjects
- *
PROGESTERONE , *GRANULOSA cell tumors , *FOLLICULAR dendritic cells , *ANTIGEN presenting cells , *CYCLIC-AMP-dependent protein kinase - Abstract
Highlights • Immortalized rat granulosa cells isolated from pre ovulatory follicles produce PGE 2. • PMSG, forskolin and a cAMP analog increase progesterone but not PGE 2 media levels. • In contrast, TPA stimulates PGE 2 but not progesterone secretion from the cells. • PKA and PKC have opposite effects on progesterone and PGE 2 secretion from the cells. • This may be beneficial to coordinate two key mediators in the preovulatory follicle. Abstract Follicular cells from various species secrete steroids and prostaglandins, which are crucial for reproduction, in response to gonadotropins. Here, we examined prostaglandin E 2 (PGE 2) secretion from immortalized rat granulosa cells derived from preovulaotry follicles expressing the rat follicle stimulating hormone receptor (denoted as FSHR cells) that produce progesterone in response to gonadotropins. The cells were stimulated with a) pregnant mare's serum gonadotropin (PMSG; a rat FSH receptor agonist), b) activators of the protein kinase A (PKA) pathway (forskolin and a cell permeable cAMP analog Dibutyryl-cAMP (DB-cAMP)) and c) protein kinase C (PKC) (12-O-tetradecanoylphorbol 13-acetate; TPA), alone and in combination for 24 h. Thereafter, PGE 2 and progesterone levels in the culture media were determined. In accordance with previous studies, while PMSG and the PKA pathway activators induced progesterone accumulation in the media, TPA did not. In contrast, our data indicate that TPA, but neither PMSG, forskolin and DB-cAMP evoked PGE 2 accumulation in the media. Western Blot analysis of cell lysate showed a drastic TPA induced increase of COX-2 levels, which was not seen with neither PMSG nor forskolin treatment. This association between the COX-2 and PGE 2 levels suggests that the enzyme activity is the likely factor that determines the synthesis and levels of the prostaglandin in the culture media of the granulosa-derived cells. The addition of the PKA inhibitor H-89 to the FSHR cultures suppressed the gonadotropin and forskolin induction of progesterone secretion. Incubation in the presence of GF109203X (a PKC inhibitor) attenuated the TPA induced PGE 2 accumulation in the culture media of the cells (a dose dependent reduction of 40–70%). In addition, while TPA inhibited the PMSG and forskolin induced-accumulation of progesterone in the media, the gonadotropin and forskolin inhibited the elevation of PGE 2 levels evoked by TPA (a dose dependent decrease of 35–55%). These data suggest that cAMP/PKA and PKC signaling have opposite effects on PGE 2 and progesterone synthesis in FSHR cells. We propose that this PKA and PKC interplay on progesterone and PGE 2 may be advantageous for the coordination of these key mediators for successful ovulation and luteinization. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. Effects of aqueous extract of Notobasis syriaca on lipopolysaccharide--induced inflammation in rats.
- Author
-
Azab, Abdullatif, Nassar, Ahmad, Kaplanski, Jacob, Mahajneh, Reem, Agam, Galila, and Azab, Abed N.
- Abstract
Objective: To investigate the effects of a dry aqueous extract of Notobasis syriaca (N. syriaca) on lipopolysaccharide (LPS)-induced inflammation in rats. Methods: Rats were fed the dried extract [500 mg/(kg•d)] for three consecutive days and then were intraperitoneally injected with LPS (1 mg/kg). Two hours after LPS injection, rats were sacrificed and blood and brain regions were collected. Inflammatory mediators' levels in plasma and homogenates of brain regions were determined by ELISA. Results: Pretreatment with the N. syriaca extract resulted in significant anti-inflammatory effects (P<0.05), including: i) attenuated LPS-induced hypothermia; ii) decreased hypothalamus and hippocampus prostaglandin E2 levels in the LPStreated rats; and, iii) reduced hypothalamus and hippocampus interleukin-6 and tumor necrosis factor-αlevels in the LPS-treated rats. Conclusions: These results suggest that N. syriaca possesses anti-inflammatory properties. Thus, it is possible that long-term consumption of this plant may result in beneficial pharmacological effects. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
32. Lymphocyte Phospho-Ser-9-GSK-3β/Total GSK-3β Protein Levels Ratio Is Not Affected by Chronic Lithium or Valproate Treatment in Euthymic Patients With Bipolar Disorder.
- Author
-
Azab, Abed N., Vainer, Ella, Agam, Galila, and Bersudsky, Yuly
- Published
- 2017
- Full Text
- View/download PDF
33. Anti-Inflammatory Activity of Natural Products.
- Author
-
Azab, Abdullatif, Nassar, Ahmad, and Azab, Abed N.
- Subjects
INFLAMMATION ,ANTI-inflammatory agents ,PLANT extracts ,NATURAL products ,MEDICINAL plants - Abstract
This article presents highlights of the published literature regarding the anti-inflammatory activities of natural products. Many review articles were published in this regard, however, most of them have presented this important issue from a regional, limited perspective. This paper summarizes the vast range of review and research articles that have reported on the anti-inflammatory effects of extracts and/or pure compounds derived from natural products. Moreover, this review pinpoints some interesting traditionally used medicinal plants that were not investigated yet. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
34. Whether lithium inhibits glycogen synthase kinase (GSK)-3β activity in vivo in humans is still an open question.
- Author
-
Agam, Galila and Azab, Abed N
- Subjects
- *
GLYCOGEN synthase kinase-3 , *BIPOLAR disorder , *THERAPEUTICS , *THERAPEUTIC use of lithium , *GLYCOGEN synthase kinase , *PHOSPHORYLATION - Abstract
The author discusses the potential suppression of glycogen synthase kinase (GSK)-3β activity in human through lithium. Topics discussed include the study "Glycogen synthase kinase-3β in patients with bipolar I disorder-results from a prospective study," by A. Jacoby and colleagues, the use of phosphorylation on controlling the GSK-3β, and the utilization of lithium as treatment for bipolar disorder.
- Published
- 2016
- Full Text
- View/download PDF
35. Effects of olanzapine on LPS-induced inflammation in rat primary glia cells.
- Author
-
Faour-Nmarne, Caroline and Azab, Abed N.
- Subjects
- *
OLANZAPINE , *ANTI-inflammatory agents , *ANTIPSYCHOTIC agents , *PATHOLOGICAL physiology , *INFLAMMATORY mediators - Abstract
Olanzapine (OLZ) is an atypical antipsychotic drug that also has mood-stabilizing effects. The mechanism of action of OLZ is not fully understood. Accumulating data suggest that inflammation plays a role in the pathophysiology of mental disorders and that psychotropic drugs exhibit some anti-inflammatory properties. This study was undertaken to examine the effects of OLZ on LPS-induced inflammation in rat primary glia cells. Glia cells were extracted from newborn rat brains. OLZ (1 or 50 µM) was added to culture medium at 6 or 72 h before addition of LPS for another 18 h, and levels of IL-10, prostaglandin (PG) E2, NO and TNF-α, and expression of cyclo-oxygensase (COX)-2 and inducible NO synthase (iNOS) were determined. Treatment with 50 µM OLZ (but not 1 µM) significantly decreased LPS-induced secretion of IL-10, PGE2 and TNF-α. In contrast, 50 µM OLZ significantly increased NO levels. OLZ did not alter the expression of COX-2 or iNOS in LPS-treated cells. These results suggest that OLZ differently affects the secretion of inflammatory mediators. Most of the significant effects of OLZ were obtained when 50 µM was used, which is a high and probably therapeutically irrelevant concentration. Therefore, under the conditions used in the present study OLZ seemed to lack a potent anti-inflammatory effect. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
36. Effects of Acute Lithium Treatment on Brain Levels of Inflammatory Mediators in Poststroke Rats.
- Author
-
Boyko, Matthew, Nassar, Ahmad, Kaplanski, Jacob, Zlotnik, Alexander, Sharon-Granit, Yael, and Azab, Abed N.
- Subjects
THERAPEUTIC use of lithium ,INFLAMMATORY mediators ,STROKE ,LABORATORY rats ,NEUROPROTECTIVE agents ,TUMOR necrosis factors ,INTERLEUKIN-6 ,DINOPROSTONE - Abstract
Stroke is a leading cause of mortality and morbidity worldwide. Few therapeutic options with proven efficacy are available for the treatment of this disabling disease. Lithium is the gold standard treatment for bipolar disorder. Moreover, lithium has been shown to exhibit neuroprotective effects and therapeutic efficacy as a treatment of other neurological disorders. This study was undertaken to examine the effects of lithium on brain inflammatory mediators levels, fever, and mortality in postischemic stroke rats. Ischemic stroke was induced by occlusion of the mid cerebral artery (MCAO). Pretreatment with a single dose of lithium at 2 hours before MCAO induction significantly reduced the elevation in interleukin- (IL-) 6 and prostaglandin E2 levels in brain of post-MCAO rats, as compared to vehicle-treated animals. On the other hand, lithium did not affect the elevation in IL-1α, IL-10, IL-12, and tumor necrosis factor-α levels in brain of post-MCAO rats. Moreover, pretreatment with lithium did not alter post-MCAO fever and mortality. These results suggest that acute pretreatment with a single dose of lithium did not markedly affect post-MCAO morbidity and mortality in rats. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
37. Inositol Phosphates and Phosphoinositides in Health and Disease.
- Author
-
Robin Harris, J., Biswas, B. B., Quinn, P., Majumder, A. Lahiri, Shi, Yihui, Azab, Abed N., Thompson, Morgan N., and Greenberg, Miriam L.
- Abstract
In the past two decades, considerable progress has been made toward understanding inositol phosphates and PI metabolism. However, there is still much to learn. The present challenge is to understand how inositol phosphates and PIs are compartmentalized, identify new targets of inositol phosphates and PIs, and elucidate the mechanisms underlying spatial and temporal regulation of the enzymes that metabolize inositol phosphates and PIs. Answers to these questions will help clarify the mechanisms of the diseases associated with these molecules and identify new possibilities for drug design. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
38. A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats.
- Author
-
Rubin, Elina, Pippione, Agnese C., Boyko, Matthew, Einaudi, Giacomo, Sainas, Stefano, Collino, Massimo, Cifani, Carlo, Lolli, Marco L., Abu-Freha, Naim, Kaplanski, Jacob, Boschi, Donatella, and Azab, Abed N.
- Subjects
NF-kappa B ,ENCEPHALITIS ,ISCHEMIC stroke ,RATS - Abstract
Aim: Nuclear factor kappa B (NF-κB) is known to play an important role in the inflammatory process which takes place after ischemic stroke. The major objective of the present study was to examine the effects of MEDS-23, a potent inhibitor of NF-κB, on clinical outcomes and brain inflammatory markers in post-ischemic stroke rats. Main methods: Initially, a Toxicity Experiment was performed to determine the appropriate dose of MEDS-23 for use in animals, as MEDS-23 was analyzed in vivo for the first time. We used the middle cerebral artery occlusion (MCAO) model for inducing ischemic stroke in rats. The effects of MEDS-23 (at 10 mg/kg, ip) on post-stroke outcomes (brain inflammation, fever, neurological deficits, mortality, and depression- and anxiety-like behaviours) was tested in several efficacy experiments. Key findings: MEDS-23 was found to be safe and significantly reduced the severity of some adverse post-stroke outcomes such as fever and neurological deficits. Moreover, MEDS-23 significantly decreased prostaglandin E2 levels in the hypothalamus and hippocampus of post-stroke rats, but did not prominently alter the levels of interleukin-6 and tumor necrosis factor-α. Significance: These results suggest that NF-κB inhibition is a potential therapeutic strategy for the treatment of ischemic stroke. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. The neuro-behavioral profile in rats after subarachnoid hemorrhage
- Author
-
Boyko, Matthew, Azab, Abed N., Kuts, Ruslan, Gruenbaum, Benjamin Fredrick, Gruenbaum, Shaun Evan, Melamed, Israel, Brotfain, Evgeny, Shapira, Yoram, Cesnulis, Evaldas, and Zlotnik, Alexander
- Subjects
- *
SUBARACHNOID hemorrhage , *PATHOLOGICAL physiology , *GAIT disorders , *ANXIETY , *MENTAL depression , *LABORATORY rats - Abstract
Abstract: Despite significant advancements in the understanding of the pathophysiological mechanisms of subarachnoid hemorrhage (SAH), little is known about the emotional consequences. The primary goal of this study was to describe the locomotor and behavioral patterns in rats following both a single-injection and double-injection model of SAH. In 48 rats, SAH was induced by injecting 0.3ml of autologous arterial blood into the cisterna magnum (single-hemorrhagic model). In 24 of these rats, post-SAH vasospasm was induced by a repeated injection of blood into the cisterna magnum 24h later (double-hemorrhagic model). In 24 additional rats, 0.3ml of saline was injected into the cisterna magnum (sham group). Neurological performance was assessed at 24, 48h, 1, 2 and 3 weeks after SAH. Four behavioral tests were performed for 3 weeks after SAH for the duration of 6 consequent days, in the following order: open field test, sucrose preference test, elevated plus maze test and forced swimming test. Following both, a single and double-hemorrhagic models of SAH, rats were found to have significant behavioral abnormalities on the open field test, sucrose preference test, elevated plus maze test, and forced swimming test. A more prominent disability was found in rats that underwent the double-hemorrhagic model of SAH than rats that underwent the single-hemorrhagic model. Both a single and double injection model of rats SAH are associated with significant behavioral disturbances including locomotor abnormalities, depressive behavior and increased anxiety, even as early as 3 weeks after SAH. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
40. Normobaric Hyperoxia Treatment of Schizophrenia.
- Author
-
Bloch, Yehudit, Applebaum, Julia, Osher, Yamima, Amar, Shirly, Azab, Abed N., Agam, Galila, Belmaker, R. H., and Bersudsky, Yuly
- Published
- 2012
- Full Text
- View/download PDF
41. Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells.
- Author
-
Nahman, Sigalit, Belmaker, RH, and Azab, Abed N
- Subjects
BIPOLAR disorder ,THERAPEUTICS ,ENDOTOXINS ,INFLAMMATION ,LABORATORY rats ,NEUROGLIA ,THERAPEUTIC use of lithium ,PROSTAGLANDINS ,CYTOKINES - Abstract
Lithium is the gold-standard treatment for bipolar disorder, a severe mental illness. A large body of evidence suggests that inflammation plays a role in the pathogenesis of bipolar disorder and that mood stabilizers exhibit anti-inflammatory properties. However, contradicting findings have also been reported. In this study, we examined the effects of lithium on LPS-induced inflammation in rat primary glia cells. Cells were pre-treated with lithium (1 or 10 mM) for 6 or 24 h, after which, inflammation was induced by the addition of LPS (for another 18 h) to the culture medium. Thereafter, medium was collected and cells were harvested for further analyses. Levels of TNF-α, IL1-β and PGE2 were determined by ELISA and NO levels by the Griess reaction assay. Expression levels of cyclooxygenase-2 (COX-2) and inducible NO synthase (iNOS) were examined by Western blot analysis. We found that pre-treatment with lithium 10 mM (but not 1 mM) significantly reduced LPS-induced secretion of TNF-α, IL1-β, PGE2 and NO. In addition, lithium significantly reduced the expression of COX-2 and iNOS. These findings indicate that lithium exhibits a potent anti-inflammatory effect. However, it’s important to emphasize that this effect was obtained mainly under treatment with an extra-therapeutic concentration of the drug. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
42. Clopidogrel and Proton Pump Inhibitors: Is There a Significant Drug-Drug Interaction?
- Author
-
Shmulevich, Emilia, Friger, Michael, Gilutz, Harel, and Azab, Abed N.
- Abstract
Copyright of Canadian Journal of Cardiovascular Nursing is the property of Canadian Council of Cardiovascular Nurses (CCCN) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2011
43. Yeast bioassay for identification of inositol depleting compounds.
- Author
-
Ding, Daobin, Shi, Yihui, Shaltiel, Galit, Azab, Abed N., Pullumbi, Ervin, Campbell, Adam, Mehta, Dhara V., Agam, Galila, and Greenberg, Miriam L.
- Subjects
YEAST ,BIOLOGICAL assay ,LITHIUM ,VALPROIC acid ,CARBAMAZEPINE - Abstract
Bipolar affective disorder is a chronic, severe, debilitating illness affecting 1-2% of the population. Valproate, along with lithium and carbamazepine, are the only drugs for which long-term efficacy has been established. However, these drugs are ineffective for, and not well tolerated by, a large number of patients and are also associated with teratogenicity and reproductive defects. Therefore, there is a substantial need to develop more effective anti-bipolar drugs. We have previously shown that valproate, like lithium, decreases intracellular inositol, which supports the inositol depletion hypothesis. We employed inositol depletion in yeast as a screening tool to identify potential new anti-bipolar medications. We show here that hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, ethylhexanoate, and methyloctanoate decrease intracellular inositol levels and increase the expression of INO1, the gene encoding myo-inositol-3-phosphate synthase (MIPS). Similar to valproate, these inositol-depleting carboxylic acids inhibited MIPS indirectly. A correlation was shown between cell growth inhibition and the increase in INO1 expression by the carboxylic acids, factors that were reversed in the presence of inositol. Inositol depletion in yeast may be exploited as an easy and inexpensive screening test for potential new inositol depleting anti-bipolar drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
44. Safety and Efficacy of Combined Low-Dose Lithium and Low-Dose Aspirin: A Pharmacological and Behavioral Proof-of-Concept Study in Rats.
- Author
-
Shvartsur, Rachel, Agam, Galila, Shnaider, Alla, Uzzan, Sarit, Nassar, Ahmad, Jabarin, Adi, Abu-Freha, Naim, Meir, Karen, and Azab, Abed N.
- Subjects
ASPIRIN ,ANXIETY ,CYSTATIN C ,STOMACH ulcers ,CHRONIC kidney failure ,TREATMENT effectiveness ,HUMAN behavior models - Abstract
Despite established efficacy in bipolar disorder patients, lithium (Li) therapy has serious side effects, particularly chronic kidney disease. We examined the safety and behavioral effects of combined chronic low-dose aspirin plus low-dose Li in rats to explore the toxicity and therapeutic potential of this treatment. Rats were fed regular or Li-containing food (0.1% [low-dose, LLD-Li] or 0.2% [standard-dose, STD-Li]) for six weeks. Low-dose aspirin (1 mg/kg) was administered alone or together with Li. Renal function and gastric mucosal integrity were assessed. The effects of the combination treatment were evaluated in depression-like and anxiety-like behavioral models. Co-treatment with aspirin did not alter plasma Li levels. Chronic STD-Li treatment resulted in significant polyuria and polydipsia, elevated blood levels of creatinine and cystatin C, and increased levels of kidney nephrin and podocin—all suggestive of impaired renal function. Aspirin co-treatment significantly damped STD-Li-induced impairments in kidney parameters. There were no gastric ulcers or blood loss in any treatment group. Combined aspirin and LLD-Li resulted in a significant increase in sucrose consumption, and in the time spent in the open arms of an elevated plus-maze compared with the LLD-Li only group, suggestive of antidepressant-like and anxiolytic-like effects, respectively. Thus, we demonstrate that low-dose aspirin mitigated the typical renal side effects of STD-Li dose and enhanced the beneficial behavioral effects of LLD-Li therapy without aggravating its toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. Effects of estrogen against LPS-induced inflammation and toxicity in primary rat glial and neuronal cultures.
- Author
-
Tenenbaum, Meytal, Azab, Abed N., and Kaplanski1, Jacob
- Subjects
- *
ESTROGEN , *ENDOTOXINS , *INFLAMMATORY mediators , *TREATMENT of diseases in women , *NEUROGLIA , *CELL death , *IMMUNOASSAY , *NEURODEGENERATION - Abstract
Several lines of evidence link inflammation with neurodegenerative diseases, which are aggravated by the age-related decline in estrogen levels in postmenopausal women. Lipopolysaccharide (LPS) is used widely to stimulate glial cells to produce pro-inflammatory mediators such as NO, PGE2, and TNF-α, and was found to be toxic in high doses. We examined the effects of a physiological dose of 17β-estradiol (E2) against LPS-induced inflammation and toxicity (cell death) in rat primary glial and neuronal cultures. Cultures were treated with 0.1 nM E2 for 24 h and then exposed to LPS 0.5-200 µg/ml for another 24 h. Levels of NO, PGE2, and TNF-α in the culture medium were determined by the Griess reaction assay, radio-immunoassay, and enzyme-linked immunoassay, respectively. Cell death was quantified by measuring the leakage of lactate dehydrogenase (LDH) into the medium from dead or dying cells using the non-radioactive cytotoxicity assay. E2 significantly reduced the LPS-induced increase in NO and TNF-α (but not PGE2) production in glial cells. PGE2 and TNF-α were undetectable in neuronal cultures, while only basal levels of NO were detected, even after stimulation with LPS. Moreover, pretreatment with E2 significantly reduced LPS-induced cell death, as measured by the release of LDH, in both glial and neuronal cultures. These results suggest that the neuroprotective effects attributed to E2 are derived, at least in part, from its anti-inflammatory and cytoprotective effects in both glial and neuronal cells. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
46. Vagotomy attenuates the effect of lipopolysaccharide on body temperature of rats in a dose-dependent manner.
- Author
-
Azab, Abed N. and Kaplanski, Jacob
- Abstract
There is a growing body of evidence suggesting that vagal afferents play a major role in peripheral-neural communication. This study was undertaken to determine whether a dose-dependent effect of lipopolysaccharide (LPS) on vagotomy-induced febrile unresponsiveness exists, and to examine the effect of vagotomy on LPS-induced increase in hypothalamic prostaglandin E2 (HT PGE2) production. Vagotomized and sham-operated rats were subjected to two experimental protocols. In the first, vagotomized and sham-operated rats were injected intraperitonealy with different doses of LPS (200, 500 and 1000 µg/kg) in order to examine the dose-dependent effect of LPS on the biphasic febrile response of the rats. In the second protocol, vagotomized and sham-operated rats were injected intraperitonealy with LPS (500 µg/kg). Two hours post injection, body temperature was measured, the rats were decapitated and blood was collected. Simultaneously, the rats' hypothalami were excised and incubated for 1 h in a Krebs-Henseleit buffer. Next, HT PGE2 was determined by radioimmunoassay. Vagotomy-induced gastric enlargement was then measured to examine the correlation between the magnitude of the enlargement and that of the vagotomy-related febrile unresponsiveness. It was found that vagotomized-induced febrile unresponsiveness is a dose-dependent effect. Subdiaphragmatic resection of the vagus prevented the biphasic febrile response caused by the lowest dose (200 µg/kg) of LPS, whereas the highest dose of LPS (1000 µg/kg) caused a similar biphasic febrile response in both vagotomized and sham-operated rats. Indeed, vagotomy attenuates LPS-induced increase in HT PGE2, and blocks the hypothermic phase of the febrile response. On the other hand, no correlation between gastric enlargement and febrile unresponsiveness was found. The results of the present study may cast further light on the crucial role of the vagus nerve as a peripheral-neural pathway in the mediation of the febrile response. [ABSTRACT FROM PUBLISHER]
- Published
- 2001
- Full Text
- View/download PDF
47. Anti-TNF-α Compounds as a Treatment for Depression.
- Author
-
Uzzan, Sarit and Azab, Abed N.
- Subjects
- *
MENTAL depression , *BIPOLAR disorder , *AFFECTIVE disorders , *TUMOR necrosis factors , *MENTAL illness , *PATIENTS' families - Abstract
Millions of people around the world suffer from psychiatric illnesses, causing unbearable burden and immense distress to patients and their families. Accumulating evidence suggests that inflammation may contribute to the pathophysiology of psychiatric disorders such as major depression and bipolar disorder. Copious studies have consistently shown that patients with mood disorders have increased levels of plasma tumor necrosis factor (TNF)-α. Given these findings, selective anti-TNF-α compounds were tested as a potential therapeutic strategy for mood disorders. This mini-review summarizes the results of studies that examined the mood-modulating effects of anti-TNF-α drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders.
- Author
-
Perrone, Maria Grazia, Centonze, Antonella, Miciaccia, Morena, Ferorelli, Savina, Scilimati, Antonio, and Azab, Abed N.
- Subjects
MENTAL illness ,AUTISM spectrum disorders ,BIPOLAR disorder ,ANTI-inflammatory agents ,PSYCHIATRIC treatment - Abstract
According to the World Health Organization, the major psychiatric and neurodevelopmental disorders include major depression, bipolar disorder, schizophrenia, and autism spectrum disorder. The potential role of inflammation in the onset and progression of these disorders is increasingly being studied. The use of non-steroidal anti-inflammatory drugs (NSAIDs), well-known cyclooxygenase (COX) inhibitors, combined with first-choice specific drugs have been long investigated. The adjunctive administration of COX inhibitors to classic clinical treatments seems to improve the prognosis of people who suffer from psychiatric disorders. In this review, a broad overview of the use of COX inhibitors in the treatment of inflammation-based psychiatric disorders is provided. For this purpose, a critical analysis of the use of COX inhibitors in the last ten years of clinical trials of the major psychiatric disorders was carried out. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
49. Psychotropic drugs attenuate lipopolysaccharide-induced hypothermia by altering hypothalamic levels of inflammatory mediators in rats.
- Author
-
Nassar, Ahmad, Sharon-Granit, Yael, and Azab, Abed N.
- Subjects
- *
HYPOTHERMIA treatment , *PSYCHIATRIC drugs , *LIPOPOLYSACCHARIDES , *INFLAMMATORY mediators , *MENTAL illness , *PATHOLOGICAL physiology , *LABORATORY rats - Abstract
Recent evidence suggests that inflammation may contribute to the pathophysiology of mental disorders and that psychotropic drugs exert various effects on brain inflammation. The administration of bacterial endotoxin (lipopolysaccharide, LPS) to mammals is associated with robust production of inflammatory mediators and pathological changes in body temperature. The objective of the present study was to examine the effects of four different psychotropic drugs on LPS-induced hypothermia and production of prostaglandin (PG) E 2 , tumor necrosis factor (TNF)-α and phosphorylated-p65 (P-p65) levels in hypothalamus of LPS-treated rats. Rats were treated once daily with lithium (100 mg/kg), carbamazepine (40 mg/kg), haloperidol (2 mg/kg), imipramine (20 mg/kg) or vehicle (NaCl 0.9%) for 29 days. On day 29, rats were injected with LPS (1 mg/kg) or saline. At 1.5 h post LPS injection body temperature was measured, rats were sacrificed, blood was collected and their hypothalami were excised, homogenized and centrifuged. PGE 2 , TNF-α and nuclear P-p65 levels were determined by specific ELISA kits. We found that lithium, carbamazepine, haloperidol and imipramine significantly attenuated LPS-induced hypothermia, resembling the effect of classic anti-inflammatory drugs. Moreover, lithium, carbamazepine, haloperidol and imipramine differently but significantly affected the levels of PGE 2 , TNF-α and P-p65 in plasma and hypothalamus of LPS-treated rats. The results suggest that psychotropic drugs attenuate LPS-induced hypothermia by reducing hypothalamic production of inflammatory constituents, particularly PGE 2 . The effects of psychotropic drugs on brain inflammation may contribute to their therapeutic mechanism but also to their toxicological profile. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
50. Inhibition of cyclooxygenase-1 does not reduce mortality in post-ischemic stroke rats.
- Author
-
Rostevanov, Ira S., Boyko, Matthew, Ferorelli, Savina, Scilimati, Antonio, Perrone, Maria Grazia, Kaplanski, Jacob, Zlotnik, Alexander, and Azab, Abed N.
- Subjects
- *
TUMOR necrosis factors , *INFLAMMATION , *RATS , *STROKE , *NEUROLOGICAL disorders , *ISCHEMIC preconditioning - Abstract
• Inflammation contributes to the pathophysiology of several neurological disorders, including ischemic stroke. • Post-ischemic brain is characterized by a prominent inflammatory response. • The involvement of cyclooxygenase (COX)-1 enzyme in post-ischemic stroke inflammation is not fully understood. • A highly selective inhibitor of COX-1 – mofezolac – did not significantly alter neurologic deficits and mortality in post-stroke rat. • Mofezolac significantly attenuated post-stroke fever. Ischemic stroke is one of the leading causes of mortality and morbidity. The currently available non-invasive therapeutic options are not sufficiently efficacious. Post-ischemic brain is characterized by a prominent inflammatory response. Little is known about the involvement of cyclooxygenase (COX)-1 in the pathophysiology of ischemic stroke. This study was undertaken to examine the effects of a highly selective COX-1 inhibitor – mofezolac – on clinical outcomes and brain inflammatory markers in post-stroke rats. Stroke was induced by subjecting rats to permanent middle cerebral artery occlusion (MCAO). Control rats underwent a sham surgery. Rats were treated with mofezolac (50 mg/kg, intraperitoneally [ ip ]) once daily for 14 days. Control animals were treated with vehicle. Body temperature (BT), neurological score (NS) and cumulative mortality were monitored at different time points. At the end of the experiment, rats were euthanized and three brain regions (hypothalamus, hippocampus and frontal cortex) were extracted. Levels of interleukin (IL)-6, prostaglandin (PG)E 2 and tumor necrosis factor (TNF)-α in these brain regions were determined by ELISA kits. BT, NS and cumulative mortality were all significantly higher in post-MCAO rats than in sham-operated rats, irrespective of the treatment given. BT, NS and mortality rate did not differ significantly between mofezolac-treated and vehicle-treated sham-operated animals. BT was significantly lower in mofezolac-treated as compared to vehicle-treated post-MCAO rats. Mofezolac did not significantly alter NS in post-MCAO rats at any time-point. Cumulative 14-day mortality was non-significantly higher in mofezolac-treated as compared to vehicle-treated post-MCAO rats (48 % vs. 21 %, respectively; P = 0.184). Mostly, IL-6 and TNF-α levels did not differ between post-MCAO and sham-operated rats and were not affected by mofezolac treatment. In contrast, mofezolac significantly decreased PGE 2 levels in post-MCAO rats' brains. Overall, these results suggest that chronic treatment with the selective COX-1 inhibitor mofezolac did not reduce morbidity or mortality in post-stroke rats. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.